The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDirecta Plus Regulatory News (DCTA)

Share Price Information for Directa Plus (DCTA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 18.70
Bid: 18.40
Ask: 19.00
Change: 0.00 (0.00%)
Spread: 0.60 (3.261%)
Open: 18.70
High: 18.70
Low: 18.70
Prev. Close: 18.70
DCTA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Statement

1 Sep 2022 07:00

RNS Number : 8490X
Directa Plus PLC
01 September 2022
 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as retained as part of UK law by virtue of the European Union (Withdrawal) Act 2018 (as amended). Upon the publication of this announcement, this inside information is now considered to be in the public domain

 

1 September 2022

 

Directa Plus plc

("Directa Plus" or the "Company")

 

Trading Update and Notice of Results

 

Directa Plus (AIM: DCTA), a leading producer and supplier of graphene nanoplatelets based products for use in consumer and industrial markets, is pleased to provide a trading update ahead of the announcement of its half year results for the six months to 30 June 2022 on 29 September 2022.

 

Trading

Further to the AGM statement announcement on 17 June 2022, Directa Plus continues to perform strongly and has delivered robust H1 2022 results across all verticals. As a result, based on its unaudited management accounts, the Company now expects to report that total revenues for H1 2022 have grown c.39% to €5.5m (H1 2021: €3.95m), driven by strong performance across all verticals.

 

Despite the uncertainty in the macro-economic climate caused by the Ukraine war, rising inflation driven by energy cost increases, and fears of recession, the Company continues to generate growing interest and awareness from global players across its different verticals.

 

The Company is responding to the inflation trends, which in H1 2022 led to cost increases and a reduction in margins. The Company has invested in manufacturing equipment which the Board expects to deliver productivity gains and margin efficiencies in H2 that will materially reduce direct production costs.

 

The Board is confident of the Company's continued growth trend and expects to deliver revenue growth of greater than 40% year-on-year (FY2021: €8.6m).

 

Environmental Remediation

Directa Plus still awaits the final decision on the award of a significant tender in Romania for its Environmental Remediation services, and the Directors continue to believe that the Company is well positioned to win the tender.

 

The Commercial Agreement with REDA Energy Ltd to distribute Grafysorber Products continues to progress with a second order received alongside an introduction to a significant potential new customer.

 

Further Opportunities

The Company continues to deliver enhancements, based on its patented technology, to products in other areas where Directa Plus has identified significant potential commercial opportunities, including paints, water/air filtration, Lithium-Sulphur batteries and composites.

 

The Company continues to partner with leading worldwide suppliers to develop outstanding products, as highlighted by the recent patent awards for filtration, the Notice of Allowance received from the United States Patent and Trademark Office for G+® embedded polyurethane membranes, alongside the extension of the partnership with Alfredo Grassi.

 

Commenting, Giulio Cesareo, Founder and CEO of Directa Plus, said: "We are pleased with the growth and commercial progress we have achieved in the first half of the year. Directa Plus continues to gain momentum in this uncertain and challenging market and continues to make progress to commercialise our highly valuable IP portfolio. The fundraise completed in December 2021 has allowed us to accelerate growth, reduce production costs, and to develop the pipeline where we see many exciting opportunities."

 

For further information please visit http://www.directa-plus.com/ or contact:

 

Directa Plus plc

+39 02 36714458

Giulio Cesareo, CEO

 

Giorgio Bonfanti, CFO

 

 

Cenkos Securities plc (Nominated Adviser and Joint Broker)

+44 131 220 6939

Neil McDonald

Adam Rae

 

Singer Capital Markets Securities Limited (Joint Broker)

+44 20 7496 3069

Rick Thompson

Phil Davies

 

Tavistock (Financial PR and IR)

+44 20 7920 3150

Simon Hudson

 

Heather Armstrong

 

 

Notes to Editors

 

Directa Plus (www.directa-plus.com) is one of the largest producers and suppliers of graphene-based products for use in consumer and industrial markets. The Company's graphene manufacturing capability uses proprietary patented technology based on a plasma super expansion process. Starting from natural graphite, each step of Directa Plus' production process - expansion, exfoliation and drying - creates graphene-based materials and hybrid graphene materials ready for a variety of uses and available in various forms such as powder, liquid and paste.

 

This proprietary production process uses a physical process, rather than a chemical process, to process graphite into pristine graphene nanoplatelets, which enables Directa Plus to offer a sustainable, non-toxic product, without unwanted by-products.

 

Directa Plus' products are made of hybrid graphene materials and graphene nano-platelets. The products (marketed as G+(R)) have multiple applications due to its properties. These G+(R) products can be categorised into various families, with different products being suitable for specific practical applications.

 

Directa Plus was established in 2005 and is based in Lomazzo (Como, Italy) and has been listed on the AIM market of the London Stock Exchange since May 2016. Directa Plus holds the Green Economy Mark from London Stock Exchange which recognises companies that contribute to the global green economy.

 

-ends-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTSDFESFEESEDA
Date   Source Headline
15th Apr 20243:01 pmRNSNotification of major holdings
12th Apr 20247:00 amRNSGiPave® installed at Imola Circuit
25th Mar 20247:00 amRNSEUR 1,000,000 Loan Agreement Signed
22nd Mar 20247:00 amRNSCollaboration with UK-based Heathcoat Fabrics
26th Feb 20247:00 amRNSAcquisition of 49% minority interest in Setcar
31st Jan 20247:00 amRNSContract win with FORD Otosan
20th Dec 20237:00 amRNSAcquisition of groundbreaking technology
15th Dec 202311:44 amRNSExpansion of collaboration with Miguel Caballero
10th Nov 20237:00 amRNSChange of Nominated Adviser
27th Sep 20237:00 amRNSHalf-year Report
18th Sep 20237:00 amRNSStrategic collaboration with The SPECTRUM Group
8th Sep 20237:00 amRNSNotice of Interim Results
7th Sep 20237:00 amRNSSignificant contract secured with LIBERTY Galati
19th Jul 20237:00 amRNSProject tender awarded
29th Jun 20237:00 amRNSDirecta Plus receives two new Italian patents
22nd Jun 20237:00 amRNSNew concept for produced water decontamination
15th Jun 20235:40 pmRNSResult of AGM
8th Jun 20237:00 amRNSNew product launch
19th May 20237:00 amRNSPosting of Annual Report and Notice of AGM
10th May 20237:00 amRNSFinal Results
9th May 20237:00 amRNSNew contract with customer Alfredo Grassi
27th Apr 20237:00 amRNSNotice of Results Presentations
20th Mar 20237:00 amRNSNew Patent Granted
27th Feb 20237:00 amRNSTrading Update and Notice of Results
21st Dec 20227:00 amRNSNew significant contract with Pigmentsolution
5th Dec 20222:05 pmRNSSecond Price Monitoring Extn
5th Dec 20222:00 pmRNSPrice Monitoring Extension
2nd Dec 20227:00 amRNSTrading Update
29th Nov 20227:00 amRNSGrant Award
21st Nov 20227:00 amRNSDirectorate Change
28th Oct 20227:00 amRNSFirst Commercial Contract in Latin America
21st Oct 20227:00 amRNSFirst Major Commercial Contract for Gipave
17th Oct 20227:00 amRNSBoar Changes
17th Oct 20227:00 amRNSBoard Changes
29th Sep 202211:05 amRNSSecond Price Monitoring Extn
29th Sep 202211:00 amRNSPrice Monitoring Extension
29th Sep 20227:00 amRNSHalf-year Report
1st Sep 20227:00 amRNSTrading Statement
30th Aug 20227:00 amRNSUS Patent Notice
4th Aug 20227:00 amRNSPartnership Extension and US Patent Award
19th Jul 20227:00 amRNSAgreement with REDA Energy for Grafysorber
5th Jul 20227:00 amRNSSupply Agreement
22nd Jun 20227:00 amRNSGrant of Italian Filtration Patent
17th Jun 20223:40 pmRNSResult of AGM
17th Jun 20227:00 amRNSAGM Statement
19th May 20227:00 amRNSPosting of Annual Report and Notice of AGM
5th May 20227:00 amRNSFinal Results
22nd Apr 20227:00 amRNSPartnership to Develop Automotive Fabrics
4th Apr 20227:00 amRNSUS EPA Authorises Grafysorber for Use in US
7th Mar 20227:00 amRNSOxfordshire Starts Second Trial of GiPave

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.